Mindful Medical Research
Welcome,         Profile    Billing    Logout  
 2 Trials 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soto-Raices, Oscar
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Active, not recruiting
3
2196
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Active, not recruiting
2
491
Europe, Canada, Japan, US, RoW
Peresolimab, Placebo
Eli Lilly and Company
Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases
11/23
01/25
NCT05123586: A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

Terminated
2
85
Europe, US, RoW
LY3361237, Placebo
Eli Lilly and Company
Systemic Lupus Erythematosus
12/23
12/23
Quinn, Timothy
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Active, not recruiting
3
2196
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
BLAZE-1, NCT04427501: A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness

Completed
2/3
3307
US
LY3819253, LY-CoV555, Bamlanivimab, LY3832479, LY-CoV016, Etesevimab, LY3853113, bebtelovimab, Placebo
Eli Lilly and Company, AbCellera Biologics Inc., Shanghai Junshi Bioscience Co., Ltd.
COVID-19
02/23
02/23
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
Aggarwal, Rajiv
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting
3
300
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Chronic Migraine
07/25
03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Recruiting
3
325
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Episodic Migraine
11/25
11/26
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Active, not recruiting
3
2196
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
01/25
01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
03/26
03/26
Santos, Queulla Garret Ramos
SURPASS-PEDS, NCT05260021: A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

Active, not recruiting
3
99
Europe, US, RoW
Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
Eli Lilly and Company
Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
07/24
02/25
ACHIEVE-5, NCT06109311: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

Recruiting
3
520
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Type 2 Diabetes
06/25
06/25
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2620
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
04/25
12/25
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
09/25
09/27
Martinez, Renil Rodriguez
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2620
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
04/25
12/25

Download Options